| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding | |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | Entrez:933 MIM:107266 HGNC:HGNC:1643 Ensembl:ENSG00000012124 AllianceGenome:HGNC:1643 | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | |||||
| Description | CD22 molecule | |||||
| GTO ID | GTC1599 |
| Trial ID | NCT02721407 |
| Disease | Mantle Cell Lymphoma | Diffuse Large B-Cell Lymphoma | Follicular Lymphoma |
| Altered gene | CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD22 CAR-T cells |
| Generation | 2nd |
| Phase | Phase1 |
| Recruitment status | Unknown |
| Title | Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients |
| Year | 2016 |
| Country | China |
| Company sponsor | Xinqiao Hospital of Chongqing |
| Other ID(s) | CD22CART |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||||||
|
|||||||||||